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ABSTRACT  1 
Background: Few studies evaluated the impact of catheter ablation (CA) on atrial 2 
tachyarrhythmia (ATA) burden in paroxysmal atrial fibrillation (AF).  3 
Objective: In the prospective, patient-controlled CLOSE to CURE study we studied longer-4 
term impact of optimized CA on ATA burden using insertable cardiac monitors (ICM).  5 
Methods: 105 PAF patients were implanted with an ICM 65 [61-78] days before CA. CA 6 
consisted of contact force guided pulmonary vein isolation (PVI) targeting an intertag 7 
distance ≤6mm and a region-specific ablation index. Primary endpoint was reduction in ICM-8 
detected ATA burden, secondary endpoints were single-procedure freedom from ATA, 9 
quality of life (QOL), and adverse events.  10 
Results: Mean age was 62±8y, CHA2DS2-VASc score 1[1-2], left atrial diameter 43 [39-43] 11 
mm. After PVI (1.13±0.39 procedure per patient), ATA burden decreased from 2.68 [0.09-12 
15.02] % at baseline to 0 [0-0] % during the first year and 0 [0-0] % during the second 2-year 13 
(reduction in ATA burden 100 [100-100] %, p<0.001). Single-procedure freedom from any 14 
ATA was 87% at 1 year and 78% at 2-year. QOL improved significantly across all scores. 15 
Adverse events occurred in 5 (4.8%) patients.  16 
Conclusions: CA has become an effective procedure in paroxysmal AF with a major impact 17 
on ICM-detected ATA burden. Whereas conventional survival analysis suggests progressive 18 
decline in efficacy, we observed that burden reduction is maintained at longer follow-up. 19 
These data imply that ATA burden is a more optimal endpoint for assessing ablation efficacy. 20 
Clinical Trial Registration: CLOSE to CURE, NCT02925624  21 
KEYWORDS 22 





Introduction  3 
Catheter ablation (CA) is recommended in patients with drug-resistant symptomatic 4 
paroxysmal atrial fibrillation (PAF).(1,2) In PAF, pulmonary vein isolation (PVI) results in a 5 
65% single-procedure one-year freedom from atrial tachyarrhythmia (ATA),(3-6) with 6 
progressive decline of efficacy over time and recurrence of ATA mainly due to non-durable 7 
PV isolation.(7)  8 
Few studies evaluated the impact of PVI on ATA burden.(8,9) ATA burden, defined as % of 9 
time spent in ATA,(1,2,10) is associated with AF-relat d symptoms, heart failure and 10 
stroke.(11-15) 11 
In the prospective, patient-controlled CLOSE to CURE (C2C) study we determine the longer-12 
term impact of PVI on ATA burden in PAF. To reliably quantify ATA burden patients were 13 
implanted with an insertable cardiac monitor (ICM) at least 2 months before PVI. Ablation 14 
consisted of a point-by-point contact force (CF)-guided RF approach aiming to enclose the 15 
PVs with contiguous, stable and optimized RF lesions.(16-19)  16 
 17 
Methods  18 
Study design 19 
The C2C study (NCT02925624) is a single-center, patient-controlled, prospective cohort 20 
study. Enrollment started July 2016 until July 2017 at the St Jan Hospital Bruges. Written 21 
informed consent was obtained before patient inclusion. The study was approved by the 22 
ethics review board.  23 
Patient population 24 
5 
 
Patients were eligible if there was a history of symptomatic ECG-proven PAF (either 1 
resistant, intolerant or unwilling to take ADT) with at least ≥3 AF episodes (anamnestic or 2 
documented) in the last 3 months.  3 
Exclusion criteria were persistent AF, prior AF ablation, left atrial (LA) diameter >50mm, 4 
ejection fraction <35%, AF secondary to reversible causes, unstable angina or uncontrolled 5 
heart failure, myocardial infarction or CABG within the last 3 months, awaiting cardiac 6 
surgery, diagnosed atrial myxoma or thrombus, acute illn ss, blood clotting or bleeding 7 
abnormalities, life expectancy <12 months, pregnant or breastfeeding women, and enrollment 8 
in any other study. 9 
 10 
Implantation and programming of the ICM 11 
All ICMs (Reveal LINQTM, Medtronic Inc.) were insertedover the 4th intercostal space, 12 
aiming for R-wave >0.3mV. Programming of ATA detection was standardized across 13 
patients (AF/AT detection: on; sensitivity: balanced; ectopy rejection: nominal; AF/AT 14 
recording threshold: all episodes). This algorithm, based upon R-R interval stability and P-15 
wave detection, has an overall accuracy for AF  detection of 99.4%.(20,21) Because the 16 
algorithm makes a rhythm classification within a 2-min window, the minimal length of an 17 
ICM-detected ATA is 2-min. To avoid memory overflow and loss of intracardiac 18 
electrograms, patients were asked to weekly transmit ICM data to the Medtronic Care Link 19 
Network.  20 
Mechanical and electrical properties of the LA 21 
All patients underwent at baseline an advanced transthoracic echocardiographic study (Vivid 22 
E9, GE-Vingmed, Milwaukee,WI) to determine LA diameter (parasternal long-axis view), 23 
LA volume (Simpson’s biplane method at end-systole) and LA strain function assessed by 2-24 
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dimensional speckle tracking (EchoPAC, GE, Norway, version 110.2). Prior to PVI, we 1 
determined atrial refractoriness, AF inducibility, electrogram voltage, and intra-atrial 2 
conduction velocity. (22) An area of low voltage was defined as an area of >1cm2 with 3 
<0.5mV.  4 
 5 
Catheter ablation 6 
PVI was performed by 6 operators. The CLOSE procedure was previously described in 7 
extenso.(17) By preference the procedure was performed under general anesthesia with an 8 
esophageal temperature monitor (SensiTherm™, St Jude Medical Inc, Minnesota, US). 9 
Further set-up consisted of a contact-force (CF) catheter (Thermocool SmartTouch ®, 10 
Biosense-Webster Inc., Diamond Bar, CA, USA) and a circular mapping catheter (CMC) 11 
(Figure 1, left panel). Identification of LA-PV junction was based upon anatomy, CF, CF 12 
vector, catheter jump during pull-back maneuvers, po ition relative to CMC, impedance and 13 
local electrogram characteristics. Maximal intertag distance was ≤6mm. In case of (pre-14 
)procedural documentation of typical flutter, cavotricuspid isthmus (CTI) ablation was 15 
performed. 16 
 17 
Study visits and follow-up after CA 18 
Clinical visits, 12-lead ECG and ICM data review were performed at enrollment, at 1, 3, 6, 19 
12, 18 and 24 months after CA or in case of symptoms. Three months after CA, ADT was 20 
stopped whereas anticoagulation was continued according to stroke risk. Quality of life 21 
(QOL) was assessed before and every 6 months after CA via the Short Form 36 Health 22 
Survey, (23) AF Symptom Checklist,(24) and EHRA symptom score. Repeat ablation was 23 
advised in case of symptomatic ATA recurrence and consisted of re-isolation or an empirical 24 
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trigger or substrate ablation.(18) 1 
 2 
Primary endpoint  3 
The primary endpoint, ICM-detected ATA burden, was defined as the % of time spent in 4 
ATA (hours of ATA/hours of monitoring) (Figure 2). ATA burden before PVI was compared 5 
to ATA burden during the first (excluding a 3-month window) and second year after PVI. All 6 
ICM-detected ATA episodes and their corresponding electrograms were revised on a weekly 7 
basis by two independent investigators (JDP, MD). This allowed to adjudicate false detection 8 
of ATA due to artefact, premature atrial or ventricular beats or sinus arrhythmia (Figure 2, 9 
upper panels). For data analysis, all true episodes and their duration were exported to a 10 
custom-made database (Figure 2, lower panels). This allowed to calculate for each patient the 11 
daily burden of ATA (black bars) and the relative time spent in ATA (%).  12 
 13 
Secondary endpoints  14 
Secondary endpoints included alternative measures of ATA burden: ATA burden before 15 
adjudication (according to raw ICM data), proportion f patients with reduction in ATA 16 
burden (by >50%, >75%, >90% and >95%) and with residual ATA burden >0.5% after CA. 17 
In addition, we calculated for each patient the number of days characterized by ATA using 18 
different cut-offs i.e. daily burden of ≥2-min, ≥1-hour, ≥6-hours or 24-hours.  19 
Other secondary endpoints were single-procedure freedom from any ICM-detected ATA (≥2-20 
min) at 1 and 2 years, QOL among the different scores and ablation-related adverse events.  21 
 22 
Sample size and statistical analysis  23 
Normality of data distribution was tested with Shapiro-Wilk test. Continuous variables were 24 
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expressed as mean with standard deviation or medians with interquartile range throughout the 1 
manuscript. Dichotomous variables were expressed as frequency (%). Group comparisons for 2 
continuous variables were performed using the paired T test or paired Wilcoxon Signed Rank 3 
test. Group comparisons for categorical variables wre performed using the Chi square test. 4 
Kaplan–Meier survival curves were used to assess time to first documented ATA recurrence.. 5 
For analysis of QOL, SF 36 data were normalized.(23-25) Statistical significance was set at 6 
0.05 for two tailed tests.  7 
For analysis of ATA burden, data were given for all patients (n=105) and for those patients 8 
with actual ICM-detected ATA during the baseline monit ring period (n=84). Simple linear 9 
regression models using baseline variables were calculated to predict ATA burden after PVI. 10 
A multivariable analysis was performed adjusting for p tentially confounding variables by 11 
selecting variables with at least p < 0.2 from the univariable analysis. All analysis was 12 
performed using SPSS software (Version 23.0, IBM, Armonk, NY, US). 13 
 14 
Results  15 
Clinical characteristics  16 
The study included 105 patients (Table 1). The median number of monitoring days was 65 17 
[61-78] days. Overall, 21 patients did not reveal any ATA episode during monitoring. In 18 
these patients the time from diagnosis to CA was 9.0 [6 5-20] months and the last ECG 19 
documented-AF episode was 17 [9-28] days before enrollment.  20 
Mechanical and electrical properties of the LA 21 
Results are summarized in Supplemental Figure 1. In0 patients (9.5%) we observed a low-22 




Procedural characteristics of CA and follow-up 2 
Results are given in Table 1. All patients except one were discharged the day after CA. 3 
Within the two-year follow-up period, 0 patients received a class IC or III antiarrhythmic 4 
drug or cardioversion, 14 patients received a repeat rocedure at 150 [100-513] days after 5 
PVI.  6 
 7 
Primary endpoint: ATA burden before and after ablation 8 
Results for ATA burden for the entire study population are given in the upper panels of 9 
Figure 3. After PVI (1.13±0.39 procedure per patient throughout 2 year follow-up), ATA 10 
burden decreased from 2.68 [0.09-15.02] % at baseline to 0 [0-0] % during the first year 11 
(reduction in ATA burden 100 [100-100] %, p<0.001, left panel) and 0 [0-0] % during the 12 
second 2-year (reduction in ATA burden 100 [100-100] %, p<0.001, right panel). Burden 13 
reduction was seen both in patients without (black bars) and with any 2-min ATA recurrence 14 
(red and green bars). None of the patients progressed to persistent AF after CA. Results for 15 
the subset of 84 patients with documented ATA during the monitoring period were similar 16 
(Figure 3, lower panels).  17 
 18 
Secondary ATA burden-related endpoints  19 
Results for the 84 patients are given in Table 2. ATA burden without adjudication decreased 20 
from 6.61 [1.80-19.00] % to 0 [0-0.03] % during the first 12 months after PVI and to 0 [0-21 
0.03] % during the second year (p<0.001 for both). The proportion of patients with >95% 22 
reduction in ATA burden was 94% and 96% at 1 and 2-y FU. Finally, throughout the first and 23 
second year after ablation, only 5 (6%) and 1 (1%) had a residual ATA burden >0.5%.  24 
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In Supplemental Figure 2, we plotted the AF calendar plots for the entire study population. 1 
Of interest, of the 14 patients with ATA during the first year, only 4 patients showed ATA 2 
during the second year. Vice versa, of the 13 patients with ATA during the second year, only 3 
4 patients showed ATA during the first year.  4 
A significant but weak regression was found between ATA burden after PVI and ATA 5 
burden before PVI (Supplemental Table 1). In a multivariable model during the 1st year 6 
adjusting for both ATA burden before PVI and male gender, only ATA burden before PVI 7 
remained statistically significant. 8 
 9 
Single-procedure, off ADT freedom from ATA 10 
In Figure 4we plotted the time to the first day with any 2-min ATA for the entire population 11 
(blue curve) and subpopulation (red curve). Single-procedure, off-ADT freedom from any 12 
ATA declined from 87% after 1 year to 78% after 2 years (p = 0.343).  13 
Quality of Life 14 
Results are summarized in Table 3. Physical and mental Health SF36 score, symptom 15 
frequency and severity scores, and EHRA score all improved significantly at 1 and 2 year 16 
(p<0.001). Improvement in QOL was comparable among patients with and without ATA 17 
recurrence.  18 
Safety 19 
Ablation-related adverse events were observed in 5 patients (4.7%): three patients with groin-20 
site hematoma (all treated conservatively by mechani al pressure), one patient with femoral 21 
pseudoaneurysm (requiring surgery) and one patient with symptomatic left PV stenosis 22 
11 
 
(treated with percutaneous stenting at 104 days after PVI with resolution of symptoms 1 
throughout 2-year FU). In none of the patients undergoing repeat ablation narrowing of PVs 2 
was observed. 3 
 4 
 5 
Discussion  6 
Main Findings 7 
The C2C study shows that a optimized CA results in a major overall reduction in ICM-8 
detected ATA burden in patients with PAF. Whereas survival analysis based upon freedom 9 
from any ATA recurrence suggests progressive declin of efficacy over time, the impact of 10 
CA on ATA burden is maintained at longer-term FU. These data imply that ATA burden is a 11 
more optimal endpoint for assessing ablation efficacy. These data imply that ATA burden is a 12 
more optimal endpoint for assessing ablation efficacy.  13 
 14 
PAF patients in the C2C study  15 
In the present study, patients were relatively young, with limited structural heart disease, low 16 
stroke risk,  near-normal left atrial diameter and relatively shorttime from diagnosis to CA.  17 
This low-risk clinical profile does not differ from the PAF patient enrolled in CA trials,(3-6) 18 
or from patients referred for CA in real-life.(26,27). Likewise ATA burden and its variation  19 
(median 2.68%) is not different from prior studies reporting on ATA burden in 20 
PAF.(8,9,14,28) Finally, C2C patients were characterized by left atrial electrical and 21 
mechanical properties in line with prior studies in PAF.(2-32). All together, above data 22 
suggest that the C2C population reflects the relatively young, symptomatic and otherwise 23 




Effect of catheter ablation on ATA burden 1 
Efficacy of CA is commonly expressed as single-procedure freedom from any ATA 2 
(>30s).(1) This definition (in which one single, even short episode implies permanent failure) 3 
most likely underestimates clinically relevant success after CA.(1) In this regard, ATA 4 
burden, defined as % of time spent in ATA, seems a more reliable estimate of clinically 5 
relevant success after CA.(1,2,10) Indeed, prior studies suggested a dose-effect relation 6 
between ATA burden and symptoms, heart failure and stroke.(11-15) Glotzer et al showed 7 
that a ≥20% ATA burden was associated with a double stroke risk(14), whereas Go et al 8 
showed that only a ≥11.4% AF burden  was associated with a >3-fold higher adjusted rate of 9 
thromboembolism in PAF patients.(13)  10 
A limited number of prospective studies reported on patient-controlled ATA burden after CA. 11 
In the DISCERN AF study, CA reduced meanICM-detected ATA burden from 8.3% to 12 
1.25% after 18 months.(9) In MANTRA-PAF, CA reduced stimated ATA burden from a 13 
90th ATA burden of 30% to 13% throughout the first 24 months.(27) In the CAPTAF study, 14 
CA reduced ICM-detected ATA burden from 24.9±37% to 5.5±18.1% at 12 months 15 
(p<0.001), not different from medical therapy.(8)  16 
In the present C2C study, optimized CA had a marked an  maintained impact on ATA 17 
burden. (with a low number or repeat procedures and without ADT). In a PAF population in 18 
which one quarter of the patients presented with ATA burden >15.02%, median ATA burden 19 
in the 1st two years after CA was 0 [IQR 0-0] % (Figure 3) and also in patients with some 20 
ATA recurrence, ATA burden was significantly reduced (because episodes were short-lasting 21 
and isolated in nature). The good results of the C2C study, most likely, are explained by 22 
durable PV isolation,(19) rather than patient selection. Also an early intervention strategy 23 
during the first year from AF diagnosis (although performed in only 26% of patients) might 24 
13 
 
contribute to improved outcome.  Whether reduction in ATA burden by CA might impact 1 
AF-related morbidity and mortality requires further study, especially in a sicker population. 2 
Marrouche et al recently showed that reduction of burden  improves outcome in heart failure 3 
patients.(15) Likewise, reduction of burden might improve symptoms,(11,12) and reduce 4 
stroke.(13,14) 5 
Single-procedure freedom from ATA, QOL, and safety after CA for PAF 6 
In the C2C study single-procedure freedom from any ATA was ≈85% at 1-year. This 7 
relatively high success rate (in the setting of continuous monitoring)(33) is in line with 1) 8 
data from the CLOSE-PILOT study,(17) 2) prior studies reporting a ≈90% 1-year success rate 9 
after multiple PVI procedures,(3,4) and 3) the knowledge that non-PV triggers account for 10 
≈10% of PAF.(34) The C2C data at 2-year (suggesting decline in efficacy as previosuly 11 
reported) (7) however underscore that this definitio  of success is not optimal to describe 12 
longer-term efficacy of CA.  13 
Prior studies showed that CA improves QOL in AF patients, especially but not exclusively in 14 
patients free from ATA.(3,5,6) Recent studies showed that residual ATA burden (i.e. >4% 15 
assessed by Holter; or >0.5% assessed by ICM) determin s poor QOL after CA.(11,12) Also 16 
in the CAPTAF study, general health was related to actual ATA burden.(8) Due to the low 17 
residual burden after CA in the C2C study, QOL significantly improved both in patients with 18 
and without ATA recurrence.  19 
The C2C study confirms the overall safety profile of CA.(3-6) Whereas we did not observe 20 
death, stroke or tamponade, there was a limited number of groin-site hematomas, one 21 
pseudoaneurysm and one PV stenosis requiring stenting. None of the patients undergoing 22 
repeat ablation revealed PV narrowing. The safety profile is in line with prior observations 23 
after CLOSE-PVI.(17,35) Moreover, improvement in safety is underappreciated because 24 
14 
 
safety of CA also depends on the number of repeat procedures required for durable isolation.  1 
 2 
Implications of the present study 3 
(1) The C2C study shows that PVI, if meticulously performed, markedly impacts ATA 4 
burden on the longer-term. It suggests that any novel CA strategy resulting in durable 5 
isolation will have similar impact; (2) Despite a class I indication, despite superiority over 6 
ADT,(3,5,6) and excellent outcome after CA combined with ADT,(24) there is 7 
underutilization and late referral of ablative therapy in PAF. The current longer-term data 8 
may lower the threshold for CA; (3) Finally, C2C data suggest that ATA burden may be a 9 
more useful measure of the outcome of the ablation tha to censor an ablation as a failure 10 
after a single 30-second recurrence as is currently recommended by the guidelines(1). 11 
Because of the short duration of false-positive ATA episodes, ATA burden is not sensitive to 12 
adjudication. Because of the shorter and isolated nature of late recurrences, ATA burden (in 13 
contrast to survival analysis) is more appropriate to assess longer-term efficacy of CA. In this 14 
regard, C2C analysis can serve as a methodological uide for future studies on ATA burden, 15 
either assessed by implanted or wearable devices. 16 
  17 
Limitations 18 
(1) Despite the importance of patient-controlled data, present results require confirmation by 19 
multi-centric large studies; (2) ATA burden is depend nt on the accuracy of ICM detection. 20 
Although one can correct for false positive ATA and although adjudication did not affect 21 
results on ATA burden, one cannot correct for false negative findings (like asymptomatic AT 22 
with slow regular ventricular rate); (3) We did not advise patients to record symptoms in a 23 
15 
 
standardized diary. Therefore the C2C study is less suited to address the issue of symptomatic 1 
vs asymptomatic ATA.(9,10); (4) Finally, 21 patients did not have ICM-documented ATA 2 
during the monitoring phase. The fact that those patients had a median time from diagnosis to 3 
CA of 9.0 [6.5-20] months together with at least 3 episodes before enrollment favors the 4 
hypothesis that absence of ATA is the result of the probabilistic nature of PAF rather than 5 
spontaneous resolution of the arrhythmia.  6 
 7 
Conclusions 8 
We observed that CA aiming for durable pulmonary vein isolation markedly reduces ATA 9 
burden assessed by insertable cardiac monitors; in a PAF population in which one quarter of 10 
the patients presented with ATA burden >15.02%, median ATA burden in the first two years 11 
after CA was 0 [IQR 0-0] %. Finally, our data make a strong case that the "survival" 12 
approach to assessing efficacy with time to first recu rence underestimates the benefit of 13 
ablation in reducing burden. 14 
 15 
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FIGURES LEGEND 2 
Figure 1: Catheter ablation  3 
Left panel: Fluoroscopic image showing position of the circular mapping catheter and 4 
ablation catheter during CA. Right panel: Tags are represented color-coded according to 5 
ablation index target.   6 
 7 
Figure 2: Analysis of atrial tachyarrhythmia burden 8 
Determining atrial tachyarrhythmia (ATA) burden from the insertable cardiac monitor. 9 
 10 
 11 
Figure 3: ATA burden plot before and after catheter ablation 12 
Plots showing the % of time spent in ATA during the first and second year compared to 13 
baseline in the entire population (upper panels) and subpopulation (lower panels). Each line 14 
represents an individual patient. Patients are arranged by recurrences during follow-up, 15 
ranging from greatest (bottom) to fewest (top). The horizontal axis is artificially truncated at 16 
30%. 17 
 18 
Figure 4: ATA-free survival plot 19 
Kaplan-Meier curves depicting time to first recurrenc  of any ATA during the first 2 years 20 








Table 1: Baseline and procedural characteristics (n = 105) 
 
Procedural characteristics  
General anaesthesia, n(%) 102(97) 
Procedure duration, min 143±31 
Isolation of all PVs, n(%) 105(100) 
Additional ablation of CTI, n(%) 6(6) 
First pass isolation right circle, n(%) 98(93) 
First pass isolation left circle, n(%) 101(96) 
Adenosine challenge performed, n(%) 97(92) 
Adenosine proof isolation, n(%) 93(96) 
RF energy, number of applications   59±11 
RF energy, total time of delivery, min 28±6 
DAP, mGy/cm² 4769±3378 
 
 
Baseline characteristics  
Age, yrs 62±8 
Male gender, n(%) 65(62) 
BMI, kg/m2 27±4 
CHA2DS2-VASc-score, median[IQR] 1[1,2] 
Arterial hypertension, n(%) 35(33) 
Diabetes, n(%) 8(8) 
Structural heart disease, n(%) 13(12) 
    Coronary artery disease, n(%) 11(10) 
    Valvular heart disease, n(%) 2(2) 
Paroxysmal AF, n(%) 105(100) 
Time from 1
st
 AF episode to PVI (months), median[IQR] 15[9,28] 
Left atrial diameter (mm), median[IQR] 43[39,43] 
Left atrial volume, ml 84±22 
ADT resistant, n(%) 63(60) 















months after PVI 
ATA burden 
throughout 12-24 
months after PVI 
P value 
ATA burden (relative time spent in 
ATA), unadjudicated % 
6.61 [1.80, 19.00] 0 [0, 0.03] 0 [0 0.03] <0.001* 
ATA burden (relative time spent in 
ATA), % 
6.56 [1.71, 17.24] 0 [0, 0] 0 [0, 0] <0.001* 
Reduction in ATA burden, % - 100 [100, 100] 100 [100, 100]  
Proportion of patients with 
reduction in ATA burden, n (%) 
    
                   By >50% - 82/84 (98) 82/84 (98) - 
                   by >75% - 81/84 (96) 81/84 (96) - 
                   by >90% - 79/84 (94) 81/84 (96) - 
                   by >95%  - 79/84 (94) 81/84 (96) - 
Proportion of patients with ATA 
burden after PVI, n (%) 
    
                   > 0.5 and ≤1 % - 1 (1) 0 (0) - 
                   > 1 and ≤5 % - 3 (3) 1 (1) - 
                   > 5 and ≤10 % - 0 (0) 0 (0) - 
                   > 10%  - 1 (1) 0 (0) - 





Table 3: Quality of Life assessment before vs after PVI 
 
 At baseline 
before PVI 
At 12 months after PVI P value At 24 months after PVI P value 
SF 36 normalised scores      
Physical health score 47.6±7.4 51.0±6.8 <0.0001 49.45±7.96 0.192 
N of fully completed forms 97 95  96  
Mental health score 48.7±9.1 52.1±7.9 0.002 52.16±8.31 <0.001 
N of fully completed forms 97 95  96  
Symptoms scores      
Symptoms frequency score 18.3±8.7 9.8±7.4 <0.0001 10.76±8.50 <0.0001 
N of fully completed forms 102 99  102  
Symptoms severity score 13.9±7.4 7.12±7.0 <0.0001 7.81±7.30 <0.0001 
N of fully completed forms 95 93  96  
EHRA score      


























ATA burden before and after PVI in all patients (n=105)
30 25 20 15 10 5 0
ATA burden = 0 
[0, 0] %
ATA burden = 2.68 
[0.04, 14.80] %
ATA burden = 0.27 
[0.003 - 1.77] %










































ATA burden = 2.68 
[0.09, 15.02] %
P < 0.001
5 10 15 20 25 30
N = 105
ATA burden = 0 [0, 0] %
AF burden reduction = 100 
[100, 100]%
ATA burden = 0 
[0, 0] %
ATA burden = 0.08 




















ATA burden = 0 [0, 0] %
AF burden reduction = 100 
[100, 100]%






















% of time spent in ATA before PVI  (65 
[61, 78] monitoring days)
% of time spent in ATA during 3-12 months 
after PVI (270 [270, 270] monitoring days)
30 25 20 15 10 5 0
ATA burden = 0 
[0, 0] %
ATA burden = 6.56 
[1.06, 16.30] %
ATA burden = 0.27 
[0.003 - 1.77] %






ATA burden = 6.55 
[1.71, 17.24] %
P < 0.001
5 10 15 20 25 30
N = 84
ATA burden = 0 [0, 0] %
AF burden reduction = 100 
[100, 100]%
P < 0.001
% of time spent in ATA before PVI  
(65 [61, 78] monitoring days)
% of time spent in ATA during 12-24 months 




































ATA burden before and after PVI in patients with ICM documented ATA before PVI (n=84)
30 25 20 15 10 5 0
ATA burden = 0 
[0, 0] %
ATA burden = 6.58 
[1.71, 16.35] %
ATA burden = 0.08 
[0.04 – 0.29] %






ATA burden = 6.55 
[1.71, 17.24] %
P < 0.001
5 10 15 20 25 30
N = 84
ATA burden = 0 [0, 0] %






































ATA burden = 2.56 
[0.07, 14.96] %
ATA burden = 4.25 
[0.53, 23.40] %
N = 105
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Freedom from any ICM documented ATA at 2 years follow-up
24211815
91 87 87 85






Patients with documented 
ATA before PVI




